Back to Search Start Over

Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors :
Deng L
Chang TZ
Wang Y
Li S
Wang S
Matsuyama S
Yu G
Compans RW
Li JD
Prausnitz MR
Champion JA
Wang BZ
Source :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2018 Aug 14; Vol. 115 (33), pp. E7758-E7767. Date of Electronic Publication: 2018 Jul 31.
Publication Year :
2018

Abstract

Influenza is a persistent threat to public health. Here we report that double-layered peptide nanoparticles induced robust specific immunity and protected mice against heterosubtypic influenza A virus challenges. We fabricated the nanoparticles by desolvating a composite peptide of tandem copies of nucleoprotein epitopes into nanoparticles as cores and cross-linking another composite peptide of four tandem copies of influenza matrix protein 2 ectodomain epitopes to the core surfaces as a coating. Delivering the nanoparticles via dissolvable microneedle patch-based skin vaccination further enhanced the induced immunity. These peptide-only, layered nanoparticles demonstrated a strong antigen depot effect and migrated into spleens and draining (inguinal) lymph nodes for an extended period compared with soluble antigens. This increased antigen-presentation time correlated with the stronger immune responses in the nanoparticle-immunized group. The protection conferred by nanoparticle immunization was transferable by passive immune serum transfusion and depended partially on a functional IgG receptor FcγRIV. Using a conditional cell depletion, we found that CD8 <superscript>+</superscript> T cells were involved in the protection. The immunological potency and stability of the layered peptide nanoparticles indicate applications for other peptide-based vaccines and peptide drug delivery.<br />Competing Interests: Conflict of interest statement: L.D. and B.-Z.W. are inventors on patents and patent applications related to this study. M.R.P. is an inventor of patents licensed to companies developing microneedle-based products, is a paid advisor to companies developing microneedle-based products, and is a founder/shareholder of companies developing microneedle-based products (Micron Biomedical).

Details

Language :
English
ISSN :
1091-6490
Volume :
115
Issue :
33
Database :
MEDLINE
Journal :
Proceedings of the National Academy of Sciences of the United States of America
Publication Type :
Academic Journal
Accession number :
30065113
Full Text :
https://doi.org/10.1073/pnas.1805713115